Is there an androgen level threshold for aneuploidy risk in infertile women?

Table 2 Comparison of androgen levels between NYU study and CHR control group

	NYU-Baseline		CHR –Baseline		CHR post DHEA
	(mean & 95% CI)		(mean & 95% CI)		(mean & 95% CI)
DHEA (ng/dL)	290.97	261.27 to 324.03¹	294.733	257.46 to 337.40	595.21	539.28 to 651.14¹
Androstenedion (ng/dL)	60.08	55.86 to 64.62²	78.98	70.56 to 88.47²	123.64	110.77 to 138.00²
Testosterone (ng/dL)	16.67	15.35 to 18.11²	21.77	19.60 to 24.18²	32.14	28.62 to 36.09²

¹P < 0.0001; ²P < 0.001; The table demonstrates that DHEA levels were similar between NYU and CHR patients at treatment start but post-DHEA supplementation CHR levels were significantly higher. Androstenedion and testosterone levels were even at baseline lower in NYU than CHR patients.

ISSN: 1477-7827